Brokerages Anticipate ContraFect Corporation (CFRX) to Announce ($0.10) Earnings Per Share

Shares of ContraFect Corporation (NASDAQ:CFRX) have been given an average broker rating score of 1.67 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.

Analysts have set a 1 year consensus price objective of $5.00 for the company and are expecting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given ContraFect an industry rank of 103 out of 265 based on the ratings given to related companies.

A number of institutional investors and hedge funds have recently bought and sold shares of CFRX. Fosun International Ltd acquired a new stake in ContraFect in the 3rd quarter valued at approximately $9,435,000. Birchview Capital LP increased its position in shares of ContraFect by 56.5% during the 3rd quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after purchasing an additional 410,000 shares during the period. Finally, White Pine Capital LLC increased its position in shares of ContraFect by 0.3% during the 2nd quarter. White Pine Capital LLC now owns 253,870 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 825 shares during the period. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Shares of ContraFect (NASDAQ CFRX) traded up $0.01 during midday trading on Thursday, hitting $0.98. The company had a trading volume of 142,416 shares, compared to its average volume of 66,893. ContraFect has a 1-year low of $0.80 and a 1-year high of $2.50.

TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Get a free copy of the Zacks research report on ContraFect (CFRX)

For more information about research offerings from Zacks Investment Research, visit

What are top analysts saying about ContraFect Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ContraFect Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit